

Automation in Biopharma Market Forecasts to 2030 – Global Analysis By Component (Automation Hardware, Automation Software, Services Project Phase, Services Operation Phase, Analytics Automation and Other Components), Mode of Automation, Technology, Application, End User and By Geography

<https://marketpublishers.com/r/A7AB543ACCB5EN.html>

Date: February 2025

Pages: 150

Price: US\$ 4,150.00 (Single User License)

ID: A7AB543ACCB5EN

Abstracts

According to Statistics MRC, the Global Automation in Biopharma Market is growing at a CAGR of 8.4% during the forecast period. Automation in biopharma is the use of advanced technologies and systems to streamline and optimize various processes in the production of biopharmaceuticals. This includes automating tasks such as cell culture, protein production, quality control, data analysis, and packaging. By integrating robotics, artificial intelligence, and machine learning, automation enhances efficiency, reduces human error, improves consistency, and accelerates time-to-market for new drugs. It plays a crucial role in ensuring regulatory compliance and cost-effective manufacturing in the biopharmaceutical industry.

Market Dynamics:

Driver:

Growing demand for personalized medicine

The growing demand for personalized medicine is driving the need for market. Personalized treatments require highly specific and scalable manufacturing processes to cater to individual patient needs, such as gene therapies and customized biologics.

Automation facilitates the precise control of these complex processes, ensuring consistency, and efficiency. By enhancing production capabilities and reducing human error, automation enables biopharma companies to meet the increasing demand for tailored therapies, while ensuring high-quality standards.

Restraint:

Data security and privacy concerns

Data security and privacy concerns in biopharma automation can lead to significant risks, including unauthorized access to sensitive patient information, intellectual property theft, and regulatory violations. Breaches may result in reputational damage, costly fines, and loss of trust from stakeholders. Inadequate data protection can also hinder innovation and collaboration, as companies may be reluctant to share critical information, ultimately delaying drug development and affecting market competitiveness.

Opportunity:

Improved data quality and consistency

Improved data quality and consistency in the market enhances decision-making, regulatory compliance, and operational efficiency. By integrating advanced technologies such as AI and machine learning, companies can minimize human errors, streamline data collection, and ensure real-time data accuracy. This leads to more reliable processes, faster drug development, and optimized manufacturing, ultimately accelerating time-to-market and reducing costs while maintaining high standards of quality and safety.

Threat:

High initial investment costs

High initial investment costs in the market can be a significant barrier for smaller companies. The substantial upfront expenses for advanced technologies, equipment, and infrastructure may delay or prevent adoption. This can result in slower innovation, reduced competitiveness, and increased financial pressure. Smaller firms may struggle to secure funding, hindering their ability to scale operations, improve efficiency, and keep pace with larger industry players.

Covid-19 Impact:

The COVID-19 pandemic accelerated the adoption of the market, highlighting the need for faster, more efficient drug development and manufacturing processes. Automation helped streamline vaccine production, clinical trials, and supply chain management. However, the pandemic also disrupted global supply chains, leading to delays and challenges in deploying new technologies. Despite these hurdles, the crisis underscored automation's role in enhancing resilience and scalability in biopharma operations.

The automation software segment is expected to be the largest during the forecast period

The automation software segment is expected to account for the largest market share during the forecast period. It integrates technologies like AI, machine learning, and data analytics to improve efficiency, reduce errors, and ensure regulatory compliance. By automating repetitive tasks, these software solutions enhance accuracy in data collection, speed up production timelines, and support real-time monitoring. This ultimately leads to lower costs, faster time-to-market, and higher product quality in the biopharma industry.

The pharmaceutical companies segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the pharmaceutical companies segment is predicted to witness the highest growth rate. By integrating automation tools like robotics, AI, and machine learning, they improve accuracy, reduce human error, and speed up production processes. These companies focus on optimizing supply chains, clinical trials, and quality control. Automation not only lowers operational costs but also accelerates innovation, ensuring faster time-to-market for critical therapies and treatments.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share driven by technological advancements and the need for more efficient drug production and development processes. With strong investments in AI, robotics, and data analytics, North American companies are optimizing manufacturing, enhancing quality control, and ensuring regulatory compliance. The region's focus on innovation,

coupled with a robust healthcare infrastructure, positions it as a global leader in biopharma automation.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR. The growing demand for biologics, biosimilars, and advanced therapies is pushing biopharmaceutical companies to adopt automation technologies to streamline production processes, improve consistency, and meet high production volumes. Additionally, the development of advanced technologies has enhanced automation systems, making them more accessible and adaptable to the biopharmaceutical industry.

Key players in the market

Some of the key players in Automation in Biopharma market include Thermo Fisher Scientific Inc., Siemens Healthineers AG, Danaher Corporation, GE HealthCare Technologies Inc., PerkinElmer, Inc., Tecan Group Ltd., Sartorius AG, Agilent Technologies, Inc., Hamilton Company, Bio-Rad Laboratories, Inc., Eppendorf AG, Bruker Corporation, Honeywell International Inc., Parker Hannifin Corporation, Rockwell Automation, Inc., Waters Corporation and Yokogawa Electric Corporation.

Key Developments:

In December 2024, Siemens Healthineers has concluded the acquisition from Novartis of Advanced Accelerator Applications Molecular Imaging, a European manufacturing and distribution network of diagnostic radiopharmaceuticals for positron emission tomography (PET) scans. The acquired company will be known as Advanced Accelerator Applications, a Siemens Healthineers company.

In June 2024, Thermo Fisher Scientific Inc., the world leader in serving science, today introduced the Thermo Scientific™ KingFisher™ PlasmidPro Maxi Processor* (PlasmidPro), the only fully automated maxi-scale plasmid DNA (pDNA) purification system. PlasmidPro enables innovation at scale, providing complete automation across mini and maxi scale purification and delivering high-purity plasmid without manual column preparation and intervention.

Components Covered:

Automation Hardware

Automation Software

Services Project Phase

Services Operation Phase

Analytics Automation

Other Components

Mode of Automations Covered:

Fully Automated Systems

Semi-Automated Systems

Technologies Covered:

Automation Technology

Digitization Technology

Applications Covered:

Research & Development

Biomanufacturing

Clinical Trials

Quality Control & Assurance

Diagnostics

Other Applications

End Users Covered:

Pharmaceutical Companies

Biopharmaceutical Companies

Contract Research Organizations (CROs)

Academic and Research Institutions

Laboratories

Other End Users

Regions Covered:

North America

US

Canada

Mexico

Europe

Germany

UK

Italy

France

Spain

Rest of Europe

Asia Pacific

Japan

China

India

Australia

New Zealand

South Korea

Rest of Asia Pacific

South America

Argentina

Brazil

Chile

Rest of South America

Middle East & Africa

Saudi Arabia

UAE

Qatar

South Africa

Rest of Middle East & Africa

What our report offers:

- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2022, 2023, 2024, 2026, and 2030
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

Company Profiling

Comprehensive profiling of additional market players (up to 3)

SWOT Analysis of key players (up to 3)

Regional Segmentation

Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)

Competitive Benchmarking

Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Contents

1 EXECUTIVE SUMMARY

2 PREFACE

- 2.1 Abstract
- 2.2 Stake Holders
- 2.3 Research Scope
- 2.4 Research Methodology
 - 2.4.1 Data Mining
 - 2.4.2 Data Analysis
 - 2.4.3 Data Validation
 - 2.4.4 Research Approach
- 2.5 Research Sources
 - 2.5.1 Primary Research Sources
 - 2.5.2 Secondary Research Sources
 - 2.5.3 Assumptions

3 MARKET TREND ANALYSIS

- 3.1 Introduction
- 3.2 Drivers
- 3.3 Restraints
- 3.4 Opportunities
- 3.5 Threats
- 3.6 Technology Analysis
- 3.7 Application Analysis
- 3.8 End User Analysis
- 3.9 Emerging Markets
- 3.10 Impact of Covid-19

4 PORTERS FIVE FORCE ANALYSIS

- 4.1 Bargaining power of suppliers
- 4.2 Bargaining power of buyers
- 4.3 Threat of substitutes
- 4.4 Threat of new entrants
- 4.5 Competitive rivalry

5 GLOBAL AUTOMATION IN BIOPHARMA MARKET, BY COMPONENT

- 5.1 Introduction
- 5.2 Automation Hardware
- 5.3 Automation Software
- 5.4 Services Project Phase
- 5.5 Services Operation Phase
- 5.6 Analytics Automation
- 5.7 Other Components

6 GLOBAL AUTOMATION IN BIOPHARMA MARKET, BY MODE OF AUTOMATION

- 6.1 Introduction
- 6.2 Fully Automated Systems
- 6.3 Semi-Automated Systems

7 GLOBAL AUTOMATION IN BIOPHARMA MARKET, BY TECHNOLOGY

- 7.1 Introduction
- 7.2 Automation Technology
 - 7.2.1 Process Automation
 - 7.2.2 Laboratory Automation
 - 7.2.3 Robotics and Artificial Intelligence
 - 7.2.4 Control Systems
 - 7.2.5 Programmable Logic Controllers (PLCs)
- 7.3 Digitization Technology
 - 7.3.1 Data Analytics and Visualization
 - 7.3.2 Electronic Lab Notebooks (ELN)
 - 7.3.3 Cloud Computing
 - 7.3.4 Internet of Things (IoT)
 - 7.3.5 Digital Twin Technology

8 GLOBAL AUTOMATION IN BIOPHARMA MARKET, BY APPLICATION

- 8.1 Introduction
- 8.2 Research & Development
 - 8.2.1 Drug Discovery
 - 8.2.2 Genomics and Proteomics

- 8.3 Biomanufacturing
 - 8.3.1 Upstream Processing
 - 8.3.2 Downstream Processing
- 8.4 Clinical Trials
- 8.5 Quality Control & Assurance
- 8.6 Diagnostics
- 8.7 Other Applications

9 GLOBAL AUTOMATION IN BIOPHARMA MARKET, BY END USER

- 9.1 Introduction
- 9.2 Pharmaceutical Companies
- 9.3 Biopharmaceutical Companies
- 9.4 Contract Research Organizations (CROs)
- 9.5 Academic and Research Institutions
- 9.6 Diagnostic Laboratories
- 9.7 Other End Users

10 GLOBAL AUTOMATION IN BIOPHARMA MARKET, BY GEOGRAPHY

- 10.1 Introduction
- 10.2 North America
 - 10.2.1 US
 - 10.2.2 Canada
 - 10.2.3 Mexico
- 10.3 Europe
 - 10.3.1 Germany
 - 10.3.2 UK
 - 10.3.3 Italy
 - 10.3.4 France
 - 10.3.5 Spain
 - 10.3.6 Rest of Europe
- 10.4 Asia Pacific
 - 10.4.1 Japan
 - 10.4.2 China
 - 10.4.3 India
 - 10.4.4 Australia
 - 10.4.5 New Zealand
 - 10.4.6 South Korea

- 10.4.7 Rest of Asia Pacific
- 10.5 South America
 - 10.5.1 Argentina
 - 10.5.2 Brazil
 - 10.5.3 Chile
 - 10.5.4 Rest of South America
- 10.6 Middle East & Africa
 - 10.6.1 Saudi Arabia
 - 10.6.2 UAE
 - 10.6.3 Qatar
 - 10.6.4 South Africa
 - 10.6.5 Rest of Middle East & Africa

11 KEY DEVELOPMENTS

- 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
- 11.2 Acquisitions & Mergers
- 11.3 New Product Launch
- 11.4 Expansions
- 11.5 Other Key Strategies

12 COMPANY PROFILING

- 12.1 Thermo Fisher Scientific Inc.
- 12.2 Siemens Healthineers AG
- 12.3 Danaher Corporation
- 12.4 GE HealthCare Technologies Inc.
- 12.5 PerkinElmer, Inc.
- 12.6 Tecan Group Ltd.
- 12.7 Sartorius AG
- 12.8 Agilent Technologies, Inc.
- 12.9 Hamilton Company
- 12.10 Bio-Rad Laboratories, Inc.
- 12.11 Eppendorf AG
- 12.12 Bruker Corporation
- 12.13 Honeywell International Inc.
- 12.14 Parker Hannifin Corporation
- 12.15 Rockwell Automation, Inc.
- 12.16 Waters Corporation

12.17 Yokogawa Electric Corporation

List Of Tables

LIST OF TABLES

- 1 Global Automation in Biopharma Market Outlook, By Region (2022-2030) (\$MN)
- 2 Global Automation in Biopharma Market Outlook, By Component (2022-2030) (\$MN)
- 3 Global Automation in Biopharma Market Outlook, By Automation Hardware (2022-2030) (\$MN)
- 4 Global Automation in Biopharma Market Outlook, By Automation Software (2022-2030) (\$MN)
- 5 Global Automation in Biopharma Market Outlook, By Services Project Phase (2022-2030) (\$MN)
- 6 Global Automation in Biopharma Market Outlook, By Services Operation Phase (2022-2030) (\$MN)
- 7 Global Automation in Biopharma Market Outlook, By Analytics Automation (2022-2030) (\$MN)
- 8 Global Automation in Biopharma Market Outlook, By Other Components (2022-2030) (\$MN)
- 9 Global Automation in Biopharma Market Outlook, By Mode of Automation (2022-2030) (\$MN)
- 10 Global Automation in Biopharma Market Outlook, By Fully Automated Systems (2022-2030) (\$MN)
- 11 Global Automation in Biopharma Market Outlook, By Semi-Automated Systems (2022-2030) (\$MN)
- 12 Global Automation in Biopharma Market Outlook, By Technology (2022-2030) (\$MN)
- 13 Global Automation in Biopharma Market Outlook, By Automation Technology (2022-2030) (\$MN)
- 14 Global Automation in Biopharma Market Outlook, By Process Automation (2022-2030) (\$MN)
- 15 Global Automation in Biopharma Market Outlook, By Laboratory Automation (2022-2030) (\$MN)
- 16 Global Automation in Biopharma Market Outlook, By Robotics and Artificial Intelligence (2022-2030) (\$MN)
- 17 Global Automation in Biopharma Market Outlook, By Control Systems (2022-2030) (\$MN)
- 18 Global Automation in Biopharma Market Outlook, By Programmable Logic Controllers (PLCs) (2022-2030) (\$MN)
- 19 Global Automation in Biopharma Market Outlook, By Digitization Technology (2022-2030) (\$MN)

- 20 Global Automation in Biopharma Market Outlook, By Data Analytics and Visualization (2022-2030) (\$MN)
- 21 Global Automation in Biopharma Market Outlook, By Electronic Lab Notebooks (ELN) (2022-2030) (\$MN)
- 22 Global Automation in Biopharma Market Outlook, By Cloud Computing (2022-2030) (\$MN)
- 23 Global Automation in Biopharma Market Outlook, By Internet of Things (IoT) (2022-2030) (\$MN)
- 24 Global Automation in Biopharma Market Outlook, By Digital Twin Technology (2022-2030) (\$MN)
- 25 Global Automation in Biopharma Market Outlook, By Application (2022-2030) (\$MN)
- 26 Global Automation in Biopharma Market Outlook, By Research & Development (2022-2030) (\$MN)
- 27 Global Automation in Biopharma Market Outlook, By Drug Discovery (2022-2030) (\$MN)
- 28 Global Automation in Biopharma Market Outlook, By Genomics and Proteomics (2022-2030) (\$MN)
- 29 Global Automation in Biopharma Market Outlook, By Biomanufacturing (2022-2030) (\$MN)
- 30 Global Automation in Biopharma Market Outlook, By Upstream Processing (2022-2030) (\$MN)
- 31 Global Automation in Biopharma Market Outlook, By Downstream Processing (2022-2030) (\$MN)
- 32 Global Automation in Biopharma Market Outlook, By Clinical Trials (2022-2030) (\$MN)
- 33 Global Automation in Biopharma Market Outlook, By Quality Control & Assurance (2022-2030) (\$MN)
- 34 Global Automation in Biopharma Market Outlook, By Diagnostics (2022-2030) (\$MN)
- 35 Global Automation in Biopharma Market Outlook, By Other Applications (2022-2030) (\$MN)
- 36 Global Automation in Biopharma Market Outlook, By End User (2022-2030) (\$MN)
- 37 Global Automation in Biopharma Market Outlook, By Pharmaceutical Companies (2022-2030) (\$MN)
- 38 Global Automation in Biopharma Market Outlook, By Biopharmaceutical Companies (2022-2030) (\$MN)
- 39 Global Automation in Biopharma Market Outlook, By Contract Research Organizations (CROs) (2022-2030) (\$MN)
- 40 Global Automation in Biopharma Market Outlook, By Academic and Research Institutions (2022-2030) (\$MN)

41 Global Automation in Biopharma Market Outlook, By Diagnostic Laboratories (2022-2030) (\$MN)

42 Global Automation in Biopharma Market Outlook, By Other End Users (2022-2030) (\$MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.

1 Executive Summary

2 Preface

2.1 Abstract

2.2 Stake Holders

2.3 Research Scope

2.4 Research Methodology

2.4.1 Data Mining

2.4.2 Data Analysis

2.4.3 Data Validation

2.4.4 Research Approach

2.5 Research Sources

2.5.1 Primary Research Sources

2.5.2 Secondary Research Sources

2.5.3 Assumptions

3 Market Trend Analysis

3.1 Introduction

3.2 Drivers

3.3 Restraints

3.4 Opportunities

3.5 Threats

3.6 Technology Analysis

3.7 Application Analysis

3.8 End User Analysis

3.9 Emerging Markets

3.10 Impact of Covid-19

4 Porters Five Force Analysis

4.1 Bargaining power of suppliers

4.2 Bargaining power of buyers

4.3 Threat of substitutes

4.4 Threat of new entrants

4.5 Competitive rivalry

5 Global Automation in Biopharma Market, By Component

5.1 Introduction

5.2 Automation Hardware

5.3 Automation Software

5.4 Services Project Phase

5.5 Services Operation Phase

5.6 Analytics Automation

5.7 Other Components

6 Global Automation in Biopharma Market, By Mode of Automation

6.1 Introduction

6.2 Fully Automated Systems

6.3 Semi-Automated Systems

7 Global Automation in Biopharma Market, By Technology

7.1 Introduction

7.2 Automation Technology

7.2.1 Process Automation

7.2.2 Laboratory Automation

7.2.3 Robotics and Artificial Intelligence

7.2.4 Control Systems

7.2.5 Programmable Logic Controllers (PLCs)

7.3 Digitization Technology

7.3.1 Data Analytics and Visualization

7.3.2 Electronic Lab Notebooks (ELN)

7.3.3 Cloud Computing

7.3.4 Internet of Things (IoT)

7.3.5 Digital Twin Technology

8 Global Automation in Biopharma Market, By Application

8.1 Introduction

8.2 Research & Development

8.2.1 Drug Discovery

8.2.2 Genomics and Proteomics

8.3 Biomanufacturing

8.3.1 Upstream Processing

8.3.2 Downstream Processing

8.4 Clinical Trials

8.5 Quality Control & Assurance

8.6 Diagnostics

8.7 Other Applications

9 Global Automation in Biopharma Market, By End User

9.1 Introduction

9.2 Pharmaceutical Companies

9.3 Biopharmaceutical Companies

9.4 Contract Research Organizations (CROs)

9.5 Academic and Research Institutions

9.6 Laboratories

9.7 Other End Users

10 Global Automation in Biopharma Market, By Geography

10.1 Introduction

10.2 North America

10.2.1 US

10.2.2 Canada

10.2.3 Mexico

10.3 Europe

10.3.1 Germany

10.3.2 UK

10.3.3 Italy

10.3.4 France

10.3.5 Spain

10.3.6 Rest of Europe

10.4 Asia Pacific

10.4.1 Japan

10.4.2 China

10.4.3 India

10.4.4 Australia

10.4.5 New Zealand

10.4.6 South Korea

10.4.7 Rest of Asia Pacific

10.5 South America

10.5.1 Argentina

10.5.2 Brazil

- 10.5.3 Chile
- 10.5.4 Rest of South America
- 10.6 Middle East & Africa
 - 10.6.1 Saudi Arabia
 - 10.6.2 UAE
 - 10.6.3 Qatar
 - 10.6.4 South Africa
 - 10.6.5 Rest of Middle East & Africa

11 Key Developments

- 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
- 11.2 Acquisitions & Mergers
- 11.3 New Product Launch
- 11.4 Expansions
- 11.5 Other Key Strategies

12 Company Profiling

- 12.1 Thermo Fisher Scientific Inc.
- 12.2 Siemens Healthineers AG
- 12.3 Danaher Corporation
- 12.4 GE HealthCare Technologies Inc.
- 12.5 PerkinElmer, Inc.
- 12.6 Tecan Group Ltd.
- 12.7 Sartorius AG
- 12.8 Agilent Technologies, Inc.
- 12.9 Hamilton Company
- 12.10 Bio-Rad Laboratories, Inc.
- 12.11 Eppendorf AG
- 12.12 Bruker Corporation
- 12.13 Honeywell International Inc.
- 12.14 Parker Hannifin Corporation
- 12.15 Rockwell Automation, Inc.
- 12.16 Waters Corporation
- 12.17 Yokogawa Electric Corporation

LIST OF TABLES

Table 1 Global Automation in Biopharma Market Outlook, By Region (2022-2030)
(\$MN)

Table 2 Global Automation in Biopharma Market Outlook, By Component (2022-2030)

(\$MN)

Table 3 Global Automation in Biopharma Market Outlook, By Automation Hardware (2022-2030) (\$MN)

Table 4 Global Automation in Biopharma Market Outlook, By Automation Software (2022-2030) (\$MN)

Table 5 Global Automation in Biopharma Market Outlook, By Services Project Phase (2022-2030) (\$MN)

Table 6 Global Automation in Biopharma Market Outlook, By Services Operation Phase (2022-2030) (\$MN)

Table 7 Global Automation in Biopharma Market Outlook, By Analytics Automation (2022-2030) (\$MN)

Table 8 Global Automation in Biopharma Market Outlook, By Other Components (2022-2030) (\$MN)

Table 9 Global Automation in Biopharma Market Outlook, By Mode of Automation (2022-2030) (\$MN)

Table 10 Global Automation in Biopharma Market Outlook, By Fully Automated Systems (2022-2030) (\$MN)

Table 11 Global Automation in Biopharma Market Outlook, By Semi-Automated Systems (2022-2030) (\$MN)

Table 12 Global Automation in Biopharma Market Outlook, By Technology (2022-2030) (\$MN)

Table 13 Global Automation in Biopharma Market Outlook, By Automation Technology (2022-2030) (\$MN)

Table 14 Global Automation in Biopharma Market Outlook, By Process Automation (2022-2030) (\$MN)

Table 15 Global Automation in Biopharma Market Outlook, By Laboratory Automation (2022-2030) (\$MN)

Table 16 Global Automation in Biopharma Market Outlook, By Robotics and Artificial Intelligence (2022-2030) (\$MN)

Table 17 Global Automation in Biopharma Market Outlook, By Control Systems (2022-2030) (\$MN)

Table 18 Global Automation in Biopharma Market Outlook, By Programmable Logic Controllers (PLCs) (2022-2030) (\$MN)

Table 19 Global Automation in Biopharma Market Outlook, By Digitization Technology (2022-2030) (\$MN)

Table 20 Global Automation in Biopharma Market Outlook, By Data Analytics and Visualization (2022-2030) (\$MN)

Table 21 Global Automation in Biopharma Market Outlook, By Electronic Lab Notebooks (ELN) (2022-2030) (\$MN)

Table 22 Global Automation in Biopharma Market Outlook, By Cloud Computing (2022-2030) (\$MN)

Table 23 Global Automation in Biopharma Market Outlook, By Internet of Things (IoT) (2022-2030) (\$MN)

Table 24 Global Automation in Biopharma Market Outlook, By Digital Twin Technology (2022-2030) (\$MN)

Table 25 Global Automation in Biopharma Market Outlook, By Application (2022-2030) (\$MN)

Table 26 Global Automation in Biopharma Market Outlook, By Research & Development (2022-2030) (\$MN)

Table 27 Global Automation in Biopharma Market Outlook, By Drug Discovery (2022-2030) (\$MN)

Table 28 Global Automation in Biopharma Market Outlook, By Genomics and Proteomics (2022-2030) (\$MN)

Table 29 Global Automation in Biopharma Market Outlook, By Biomanufacturing (2022-2030) (\$MN)

Table 30 Global Automation in Biopharma Market Outlook, By Upstream Processing (2022-2030) (\$MN)

Table 31 Global Automation in Biopharma Market Outlook, By Downstream Processing (2022-2030) (\$MN)

Table 32 Global Automation in Biopharma Market Outlook, By Clinical Trials (2022-2030) (\$MN)

Table 33 Global Automation in Biopharma Market Outlook, By Quality Control & Assurance (2022-2030) (\$MN)

Table 34 Global Automation in Biopharma Market Outlook, By Diagnostics (2022-2030) (\$MN)

Table 35 Global Automation in Biopharma Market Outlook, By Other Applications (2022-2030) (\$MN)

Table 36 Global Automation in Biopharma Market Outlook, By End User (2022-2030) (\$MN)

Table 37 Global Automation in Biopharma Market Outlook, By Pharmaceutical Companies (2022-2030) (\$MN)

Table 38 Global Automation in Biopharma Market Outlook, By Biopharmaceutical Companies (2022-2030) (\$MN)

Table 39 Global Automation in Biopharma Market Outlook, By Contract Research Organizations (CROs) (2022-2030) (\$MN)

Table 40 Global Automation in Biopharma Market Outlook, By Academic and Research Institutions (2022-2030) (\$MN)

Table 41 Global Automation in Biopharma Market Outlook, By Laboratories (2022-2030)

(\$MN)

Table 42 Global Automation in Biopharma Market Outlook, By Other End Users
(2022-2030) (\$MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.

I would like to order

Product name: Automation in Biopharma Market Forecasts to 2030 – Global Analysis By Component (Automation Hardware, Automation Software, Services Project Phase, Services Operation Phase, Analytics Automation and Other Components), Mode of Automation, Technology, Application, End User and By Geography

Product link: <https://marketpublishers.com/r/A7AB543ACCB5EN.html>

Price: US\$ 4,150.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/A7AB543ACCB5EN.html>